JP2006524242A5 - - Google Patents

Download PDF

Info

Publication number
JP2006524242A5
JP2006524242A5 JP2006509429A JP2006509429A JP2006524242A5 JP 2006524242 A5 JP2006524242 A5 JP 2006524242A5 JP 2006509429 A JP2006509429 A JP 2006509429A JP 2006509429 A JP2006509429 A JP 2006509429A JP 2006524242 A5 JP2006524242 A5 JP 2006524242A5
Authority
JP
Japan
Prior art keywords
cxcr4
peptide antagonist
sirna
antagonist
cancer cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006509429A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006524242A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/009570 external-priority patent/WO2004087068A2/en
Publication of JP2006524242A publication Critical patent/JP2006524242A/ja
Publication of JP2006524242A5 publication Critical patent/JP2006524242A5/ja
Pending legal-status Critical Current

Links

JP2006509429A 2003-03-27 2004-03-26 Ｃｘｃｒ４アンタゴニストおよびそれらの使用方法 Pending JP2006524242A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45821703P 2003-03-27 2003-03-27
PCT/US2004/009570 WO2004087068A2 (en) 2003-03-27 2004-03-26 Cxcr4 antagonists and methods of their use

Publications (2)

Publication Number Publication Date
JP2006524242A JP2006524242A (ja) 2006-10-26
JP2006524242A5 true JP2006524242A5 (enExample) 2007-05-31

Family

ID=33131767

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006509429A Pending JP2006524242A (ja) 2003-03-27 2004-03-26 Ｃｘｃｒ４アンタゴニストおよびそれらの使用方法

Country Status (5)

Country Link
US (1) US20070258893A1 (enExample)
EP (1) EP1608318A4 (enExample)
JP (1) JP2006524242A (enExample)
CA (1) CA2520406A1 (enExample)
WO (1) WO2004087068A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1635910A (zh) 2001-05-02 2005-07-06 普渡研究基金会 巨噬细胞介导的疾病的治疗和诊断
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
ES2403932T3 (es) 2002-08-27 2013-05-22 Biokine Therapeutics Ltd. Antagonista de CXCR4 y uso del mismo
WO2005103721A1 (en) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 4 (cxcr4)
MX2007008326A (es) 2005-01-07 2008-01-16 Univ Emory Antagonistas de cxcr4 para el tratamiento de una infeccion por vih.
WO2006091112A1 (en) * 2005-02-22 2006-08-31 Genesis Reasearch And Development Corporation Limited Compositions for the delivery of rna interference molecules and methods for their use
US8569280B2 (en) 2005-04-25 2013-10-29 Immune Disease Institute Methods for the treatment of multiple myeloma
US7825088B2 (en) * 2005-04-25 2010-11-02 The Cbr Institute For Biomedical Research, Inc. Methods for the treatment of multiple myeloma
DE102005023170A1 (de) * 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
US9034814B2 (en) 2005-05-25 2015-05-19 Hadasit Medical Research Services And Development Ltd. CXCR4 antagonists for wound healing and re-epithelialization
EP1904183B1 (en) 2005-07-05 2014-10-15 Purdue Research Foundation Pharmaceutical composition for the treatment of osteoarthritis
EP1951046B1 (en) * 2005-08-19 2012-07-18 Genzyme Corporation Methods to enhance chemotherapy
US8795633B2 (en) 2005-09-23 2014-08-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
WO2007058322A1 (ja) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
JP2009531283A (ja) * 2006-02-02 2009-09-03 アラーガン、インコーポレイテッド 眼系疾患の処置のための組成物および方法
US8628750B2 (en) 2006-02-27 2014-01-14 Technische Universitat Munchen Cancer imaging and treatment
WO2007143584A2 (en) * 2006-06-02 2007-12-13 Alcon Research, Ltd. RNAi-MEDIATED INHIBITION OF STROMAL CELL-DERIVED FACTOR 1-RELATED TARGETS FOR TREATMENT OF NEOVASCULARIZATION-RELATED CONDITIONS
US8080659B2 (en) 2006-07-11 2011-12-20 Emory University CXCR4 antagonists including diazine and triazine structures for the treatment of medical disorders
CA2668197A1 (en) 2006-11-03 2008-05-15 Philip S. Low Ex vivo flow cytometry method and device
US8455450B2 (en) 2006-12-21 2013-06-04 Biokine Therapeutics Ltd. Methods for obtaining a therapeutically effective amount of hematopoietic precursor cells and long term engraftment thereof
US8586595B2 (en) 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
CA2688308A1 (en) 2007-05-25 2008-12-04 Purdue Research Foundation Method of imaging localized infections
CA2699100A1 (en) * 2007-09-11 2009-04-02 Dorian Bevec Use of a peptide as a therapeutic agent
JP5690715B2 (ja) 2008-03-28 2015-03-25 アルテイリス・セラピユーテイクス ケモカイン受容体調節因子
CN103396473A (zh) 2008-11-04 2013-11-20 安科治疗公司 Cxcr4受体化合物
ES2462517T3 (es) * 2009-06-14 2014-05-23 Biokine Therapeutics Ltd. Terapia con péptidos para aumentar los niveles de plaquetas
WO2011094389A2 (en) * 2010-01-27 2011-08-04 Emory University Cxcr4 antagonists for imaging of cancer and inflammatory disorders
EP2566494B1 (en) 2010-02-26 2017-11-29 Acer Therapeutics, Inc. Cxcr4 receptor compounds
DK2613789T3 (en) * 2010-09-09 2018-07-23 Noxxon Pharma Ag SDF-1-binding nucleic acids and their use in cancer treatment
WO2012095849A1 (en) 2011-01-10 2012-07-19 Biokine Therapeutics Ltd. Peptides and compositions for the treatment of neuroectodermal derived tumors and retinoblastoma
EP2476441A1 (en) 2011-01-13 2012-07-18 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
WO2013160895A1 (en) 2012-04-24 2013-10-31 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
JP6294459B2 (ja) 2013-03-24 2018-03-14 バイオカイン・セラピューティクス・リミテッドＢｉｏｋｉｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ． 骨髄性白血病の処置方法
CA2928315C (en) 2013-10-31 2023-03-21 Biokine Therapeutics Ltd. Methods of treating acute myeloid leukemia with a flt3 mutation
WO2015114638A2 (en) 2014-02-03 2015-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of eliminating stem cells
KR101700946B1 (ko) * 2014-11-11 2017-02-02 연세대학교 산학협력단 Ｃｘｃｒ４ 길항제를 포함하는 피부 색소침착의 예방 또는 개선용 조성물
EA037555B1 (ru) * 2015-04-02 2021-04-13 Проксимэйджен, Элэлси Применение 6-{4-[1-(пропан-2-ил)пиперидин-4-ил]-1,4-диазепан-1-ил}-n-(пиридин-4-ил)пиридин-2-карбоксамида для лечения раковых заболеваний цнс
US10709697B2 (en) 2015-07-16 2020-07-14 Emory University Bis-amines, compositions, and uses related to CXCR4 inhibition
CN107921087A (zh) 2015-07-16 2018-04-17 百欧肯治疗有限公司 治疗癌症的组合物及方法
US10434195B2 (en) 2015-08-03 2019-10-08 Emory University Methylsulfonamide derivatives and uses related thereto
BR112018016924A2 (pt) 2016-02-23 2019-01-02 Biolinerx Ltd método de seleção de regime de tratamento para indivíduo que tem leucemia mieloide aguda (lma), método de maximização de resposta ao tratamento de leucemia mieloide aguda (lma), método de tratamento de lma, antagonista de cxcr4 e agente quimioterápico no tratamento de lma
EP3856225A1 (en) 2018-09-25 2021-08-04 BioLineRx Ltd. Methods of selecting treatment for cxcr4-associated cancer
CN110590744B (zh) * 2019-07-03 2021-11-02 河南省人民医院 一种靶向趋化因子受体cxcr4的小分子类pet显像剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009152A1 (en) * 1998-08-14 2000-02-24 The University Of British Columbia Therapeutic chemokine receptor antagonists
ES2403932T3 (es) * 2002-08-27 2013-05-22 Biokine Therapeutics Ltd. Antagonista de CXCR4 y uso del mismo

Similar Documents

Publication Publication Date Title
JP2006524242A5 (enExample)
Xu et al. Nuclear pore proteins and cancer
Shao et al. ALKBH5/YTHDF2‐mediated m6A modification of circAFF2 enhances radiosensitivity of colorectal cancer by inhibiting Cullin neddylation
Jančík et al. Clinical relevance of KRAS in human cancers
Ekambaram et al. The CARMA3–Bcl10–MALT1 Signalosome drives NFκB activation and promotes aggressiveness in angiotensin II receptor–positive breast cancer
Dez et al. Surveillance of nuclear-restricted pre-ribosomes within a subnucleolar region of Saccharomyces cerevisiae
Chen et al. ICP27 recruits Aly/REF but not TAP/NXF1 to herpes simplex virus type 1 transcription sites although TAP/NXF1 is required for ICP27 export
Guo et al. Exosomes: Potent regulators of tumor malignancy and potential bio-tools in clinical application
JP2018525001A5 (enExample)
Wang et al. Rapid screening of peptide probes through in situ single-bead sequencing microarray
US8772243B2 (en) Methods for predicting the response to anti-cancer treatment with an agonist of TLR7 or an agonist of TLR8
Starr et al. ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti‐cancer therapy
US20150197755A1 (en) Epcam aptamer for detection of cancer stem cells
EP3624896A1 (en) Compositions and methods for treating cancer with atypical braf mutations
JP2010514409A5 (enExample)
CN101632833B (zh) 一种前列腺癌相关的基因及其用途
Iwasaki et al. Pathology of soft‐tissue tumors: daily diagnosis, molecular cytogenetics and experimental approach
Shan et al. Mesenchymal stem cell-derived extracellular vesicles in cancer therapy resistance: from biology to clinical opportunity
Zhang et al. Docetaxel resistance-derived LINC01085 contributes to the immunotherapy of hormone-independent prostate cancer by activating the STING/MAVS signaling pathway
Miura et al. cIAP2 as a therapeutic target in colorectal cancer and other malignancies
JP2004532839A5 (enExample)
Krishnamurthy et al. Targeting the mutant PIK3CA gene by DNA‐alkylating pyrrole‐imidazole polyamide in cervical cancer
Murakami et al. Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma
Radwan et al. Functional combination of resveratrol and tamoxifen to overcome tamoxifen‐resistance in breast cancer cells
Guo et al. Ubiquitin-conjugating enzyme E2T knockdown suppresses hepatocellular tumorigenesis via inducing cell cycle arrest and apoptosis